Table 3. Carfilzomib-based studies:... | American Society of Hematology

Table 3.

Carfilzomib-based studies: comparison of PFS and OS by age and fitness⁴⁹

	ASPIRE⁵⁰						ENDEAVOR⁵¹						ARROW⁵²
PFS (median, months)	<70	KRd	28.6	Fit	KRd	31.4	<65	Kd	NE^*	Fit	Kd	NE^*	<65	1 × Kd	12.2	Fit	1 × Kd	15.7
	<70	Rd	17.6	Fit	Rd	18.9	<65	Vd	9.5	Fit	Vd	12.1	<65	2 × Kd	5.6	Fit	2 × Kd	5.7
	≥70	KRd	23.8	Frail	KRd	24.1	65-74	Kd	15.6	Frail	Kd	18.7	65-74	1 × Kd	9.2	Frail	1 × Kd	10.3
		KRd	23.8		Rd	15.9	65-74	Vd	9.5		Vd	6.6	65-74	2 × Kd	8.4		2 × Kd	6.6
		Rd	16.0				≥75	Kd	18.7				≥75	1 × Kd	12.2
		Rd	16.0				≥75	Vd	8.9				≥75	2 × Kd	9.5
OS (median, months)	<70	Not given		Fit	KRd	55.6	<65	Not given		Fit	Kd	NE^*	<65	Not given		Fit	Not given
	<70			Fit	Rd	43.3	<65			Fit	Vd	42.2	<65			Fit
	≥70			Frail	KRd	36.4	65-74			Frail	Kd	33.6	65-74			Frail
	≥70			Frail	Rd	26.2	≥75			Frail	Vd	21.8	≥75			Frail

	ASPIRE⁵⁰						ENDEAVOR⁵¹						ARROW⁵²
PFS (median, months)	<70	KRd	28.6	Fit	KRd	31.4	<65	Kd	NE^*	Fit	Kd	NE^*	<65	1 × Kd	12.2	Fit	1 × Kd	15.7
	<70	Rd	17.6	Fit	Rd	18.9	<65	Vd	9.5	Fit	Vd	12.1	<65	2 × Kd	5.6	Fit	2 × Kd	5.7
	≥70	KRd	23.8	Frail	KRd	24.1	65-74	Kd	15.6	Frail	Kd	18.7	65-74	1 × Kd	9.2	Frail	1 × Kd	10.3
		KRd	23.8		Rd	15.9	65-74	Vd	9.5		Vd	6.6	65-74	2 × Kd	8.4		2 × Kd	6.6
		Rd	16.0				≥75	Kd	18.7				≥75	1 × Kd	12.2
		Rd	16.0				≥75	Vd	8.9				≥75	2 × Kd	9.5
OS (median, months)	<70	Not given		Fit	KRd	55.6	<65	Not given		Fit	Kd	NE^*	<65	Not given		Fit	Not given
	<70			Fit	Rd	43.3	<65			Fit	Vd	42.2	<65			Fit
	≥70			Frail	KRd	36.4	65-74			Frail	Kd	33.6	65-74			Frail
	≥70			Frail	Rd	26.2	≥75			Frail	Vd	21.8	≥75			Frail

^*

not estimable.

Frailty assessment based on the IMWG frailty index.^6,53

Rd, lenalidomide and dexamethasone; Vd, bortezomib and dexamethasone.